Login to Your Account

Mina puts new RNA approach to test, starts phase I liver cancer trial

By Nuala Moran
Staff Writer

Thursday, June 2, 2016

LONDON – Mina Therapeutics Ltd. is laying claim to be first in the clinic with a novel RNA therapeutic that, in contrast to its more established siRNA gene silencing counterparts, activates dormant genes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription